Profusa Amends Acquisition Agreement, Eliminating 12% Management Share Issuance

summarizeSummary

Profusa amended its acquisition agreement for the PanOmics Assay, removing a provision for a 12% management share issuance, which significantly reduces potential future dilution for shareholders.

check_boxKey Events · M&A and Partnerships · PFSA

• Acquisition Agreement Amended

  Profusa, Inc. entered into a First Amendment to the Asset Purchase Agreement with Bio Insights LLC, originally dated April 21, 2026, for the acquisition of PanOmics Assay know-how.

• 12% Management Share Issuance Removed

  The amendment deletes Section 4.6 of the original agreement, which previously provided for the issuance of common stock equal to 12% of the fully diluted shares to the CEO and CFO for retention purposes following the closing of the acquisition and any related equity financing.

• Reduced Future Dilution

  The removal of this provision significantly reduces the potential for future dilution for existing shareholders, improving the terms of the $30 million acquisition which is to be satisfied through convertible preferred stock.

auto_awesomeAnalysis · PFSA · Industrial Applications And Services

Profusa amended its Asset Purchase Agreement with Bio Insights LLC, removing a provision that would have issued common stock equal to 12% of the fully diluted shares to management post-acquisition. This is a significant positive development for existing shareholders, as it substantially reduces potential future dilution related to the $30 million PanOmics Assay acquisition. Given Profusa's ongoing financial distress, delisting threats, and previous highly dilutive financing activities, the elimination of this large share issuance improves the terms of the acquisition for current investors.